Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Biogen to cut work force by 13 percent

November 3, 2010 4:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Biogen Idec Inc., the second largest biotechnology company in Massachusetts with approved blockbuster drugs to treat Multiple Sclerosis, has announced it will cut its work force by 13 percent, closing a site in San Diego and consolidating sites in Eastern Massachusetts into the large...

WellPoint's 3Q profit climbs 1 percent

November 3, 2010 3:45 am | by TOM MURPHY - AP Business Writer - Associated Press | News | Comments

WellPoint Inc.'s net income inched up 1 percent in the third quarter, as the insurer cut expenses and saw gains from a reduction in health care use and leftover claims that came in lower than expected.The Indianapolis insurer also raised its 2010 earnings forecast, following a third-quarter...

Cardiogenesis Receives Research Award From Federal Government

November 3, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., Nov. 3, 2010 /- Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical products used in the treatment of diffuse coronary artery disease, today announced the receipt of a grant of approximately $244,500 from the Qualifying Therapeutic Discovery Project...

TOPICS:
Advertisement

IDEV Technologies Announces FDA 510(k) Clearance for SUPERA VERITASâ„¢

November 3, 2010 3:33 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, Nov. 3, 2010 /- IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance to market the SUPERA VERITAS...

TOPICS:

Cleveland Clinic Unveils Top 10 Medical Innovations for 2011

November 3, 2010 3:32 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, Nov. 3, 2010 /- From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases. The list of breakthrough...

TOPICS:

DNA Medicine Institute Receives Qualifying Therapeutic Discovery Grant

November 3, 2010 3:32 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., Nov. 3, 2010 /- The DNA Medicine Institute, a biomedical research organization whose mission is to advance patient care, alleviate human suffering, and treat disease through innovation, has received a $222,999 grant from the U.S. government under the Qualifying...

TOPICS:

Asia Pacific Pharma Companies Turning to High-Risk, High-Reward Drug Development, According to New Report from Thomson Reuters

November 2, 2010 11:33 pm | by Bio-Medicine.Org | News | Comments

PHILADELPHIA and LONDON, Nov. 3, 2010 /- Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR...

TOPICS:

MEMSCAP: 8% net profit for the third quarter 2010

November 2, 2010 10:34 pm | by I-Micronews | News | Comments

45% revenue growth for the first 9 months of the year and continuing operations profitable over the same period.

Advertisement

Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects

November 2, 2010 7:34 pm | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Nov. 2, 2010 /- Telik, Inc. (Nasdaq: TELK ) a clinical stage drug development company focused on developing drugs to treat cancer, announced that it has been awarded grants totaling $1,222,396 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP)....

TOPICS:

Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in...

November 2, 2010 7:33 pm | by Bio-Medicine.Org | News | Comments

BASKING RIDGE, N.J., Nov. 2, 2010 /- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, presented an...

TOPICS:

Anthem Blue Cross Blue Shield Introduces Cost Disclosure Tool Throughout Colorado

November 2, 2010 3:33 pm | by Bio-Medicine.Org | News | Comments

DENVER, Nov. 2, 2010 /- Anthem Blue Cross and Blue Shield in Colorado announced today the expansion of its industry-leading transparency initiative beyond major metro areas into the entire state.  Colorado members from Silverton to Sterling and everywhere in between can now access...

TOPICS:

Improving health care in the Internet age

November 2, 2010 1:35 pm | by EurekAlert | News | Comments

(Inderscience Publishers) Faster and more widely available internet access has improved our lives in many ways but health care is lagging behind, according to researchers writing in the International Journal of Medical Engineering and Informatics.

TOPICS:

Power GaN: Market & Technology Analysis - Report from Yole Développement

November 2, 2010 12:38 pm | by I-Micronews | News | Comments

GaN Technologies for Power Electronics Applications: Industry and Market Status & Forecasts

Sapphire Market 2010, Q4 Update - A report from Yole Développement

November 2, 2010 12:38 pm | by I-Micronews | News | Comments

Acute material shortage sent 2? wafer prices in the low $30?s. Shortage to be resolved by mid 2011

New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO, Nov. 2, 2010 /- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading